Pharmacology · Diabetes Pharmacology

Oral Hypoglycemics I

Sulfonylureas, meglitinides, and metformin

Sulfonylureas and meglitinides share a common mechanism — both close K-ATP channels by binding the SUR-1 regulatory subunit, depolarizing the beta cell membrane and triggering calcium-mediated insulin exocytosis independent of ambient blood glucose; this glucose-independent insulin secretion is the direct pharmacological basis for hypoglycemia risk, which exists even when the patient is eating normally or is fasting.
Sulfonylureas and meglitinides differ primarily in duration and binding kinetics rather than mechanism: sulfonylureas bind SUR-1 with high affinity and long duration, driving sustained insulin release throughout the day; meglitinides bind with lower affinity and much shorter duration, making them meal-dependent agents — a dose is taken with each meal and skipped when a meal is skipped, reducing interprandial hypoglycemia.
Metformin's primary mechanism is inhibition of mitochondrial complex I in hepatocytes, which raises the cellular AMP/ATP ratio and activates AMP-activated protein kinase (AMPK); AMPK activation suppresses gluconeogenic enzyme expression and reduces hepatic glucose output — the mechanism is entirely hepatic and does not involve insulin secretion, which is why metformin causes no hypoglycemia as monotherapy.
The UKPDS 34 trial established that metformin reduces myocardial infarction and all-cause mortality in overweight type 2 diabetes patients independently of glycemic control — sulfonylureas and insulin produced equivalent HbA1c lowering without the same cardiovascular benefit, suggesting metformin has cardioprotective effects beyond glucose lowering that are attributable to its AMPK-mediated and non-glycemic mechanisms.
Metformin's renal contraindication is driven by lactic acidosis risk: metformin is renally cleared, accumulates in renal impairment, and impairs hepatic lactate clearance by inhibiting complex I — the combination leads to lactic acid accumulation; it is contraindicated when eGFR falls below 30 mL/min, should be used with caution between 30–45 mL/min, and must be held before iodinated contrast in patients at risk of acute kidney injury.

Abbreviations: SUR-1 = sulfonylurea receptor 1 · K-ATP = ATP-sensitive potassium channel · AMPK = AMP-activated protein kinase · eGFR = estimated glomerular filtration rate · UKPDS = United Kingdom Prospective Diabetes Study · CYP3A4 = cytochrome P450 3A4 · CKD = chronic kidney disease · HbA1c = glycated hemoglobin

Secretagogue Mechanism — Shared K-ATP Channel Pathway

Sulfonylureas and Meglitinides

K-ATP Channel Closure Cascade

Drug binds SUR-1 subunit

→

K-ATP channel closes

→

Membrane depolarizes

→

Ca²⁺ influx

→

Insulin secreted

Mechanism is identical for both drug classes. Occurs independent of blood glucose — the pharmacological basis for hypoglycemia risk even during normal eating or fasting.

Class Comparison — Secretagogues and Metformin

Class	Examples	Dosing	Hypo Risk	Key Notes
Sulfonylureas	Glipizide, glyburide, glimepiride	Once–twice daily	High	Weight gain; avoid glyburide in elderly and CKD — long active metabolites; secondary failure over time from beta cell exhaustion
Meglitinides	Repaglinide, nateglinide	With each meal	Moderate	Skip dose if skipping meal; CYP3A4 substrate; gemfibrozil dramatically raises repaglinide exposure (CYP2C8 inhibition) — contraindicated combination
Metformin	Metformin	Twice–three times daily	None	First-line agent for type 2 diabetes mellitus; weight neutral; cardiovascular benefit beyond glucose lowering (UKPDS); hold if eGFR <30; monitor vitamin B12 annually

Metformin — Mechanism and Safety

AMPK Pathway

Metformin Mechanism

Inhibits mitochondrial complex I (electron transport chain) in hepatocytes
Raises AMP/ATP ratio → activates AMP-activated protein kinase (AMPK)
AMPK activation suppresses gluconeogenic enzyme expression → reduces hepatic glucose output — primary mechanism
Improves peripheral insulin sensitivity as a secondary effect
No effect on insulin secretion → no hypoglycemia as monotherapy; safe to use alone

Contraindications and Monitoring

Metformin Safety

eGFR <30 mL/min: absolutely contraindicated — lactic acidosis risk from drug accumulation and impaired hepatic lactate clearance
eGFR 30–45 mL/min: use with caution, reduce dose, monitor more frequently
Hold before IV contrast if eGFR <30 or patient at high risk of acute kidney injury — resume 48 hours after if renal function stable
Acute heart failure or myocardial infarction: hold — tissue hypoperfusion raises lactic acidosis risk
Long-term use: monitor vitamin B12 annually — metformin reduces ileal B12 absorption
GI side effects (nausea, diarrhea): start at low dose, titrate slowly, take with food

UKPDS 34 — Metformin Cardiovascular Benefit

The United Kingdom Prospective Diabetes Study (UKPDS 34) demonstrated that metformin-treated overweight patients with type 2 diabetes mellitus had significant reductions in myocardial infarction risk and all-cause mortality compared with conventional dietary treatment — benefits not seen with sulfonylureas or insulin at equivalent glycemic control. This supports a cardioprotective effect beyond glucose lowering, likely mediated through AMPK-dependent mechanisms including reduced hepatic lipogenesis, improved endothelial function, and decreased inflammatory markers.

Ten-year follow-up data (Holman et al., 2008) confirmed that the early metformin benefit persisted long after the trial ended — a "legacy effect" consistent with durable cardiovascular risk reduction. These data underpin metformin's position as the preferred first-line agent for most patients with type 2 diabetes mellitus in current guidelines.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 41: Pancreatic Hormones and Antidiabetic Drugs	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 45: Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia	McGraw-Hill; 2023
Ashcroft FM, Rorsman P	K(ATP) channels and islet hormone secretion: new insights and controversies	Nat Rev Endocrinol. 2013;9(11):660–669
Shorr RI et al	Individual sulfonylureas and serious hypoglycemia in older people	J Am Geriatr Soc. 1996;44(7):751–755
Rosenstock J et al (CAROLINA)	Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes	JAMA. 2019;322(12):1155–1166
Fuhlendorff J et al	Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes	Diabetes. 1998;47(3):345–351
Zhou G et al	Role of AMP-activated protein kinase in mechanism of metformin action	J Clin Invest. 2001;108(8):1167–1174
Foretz M et al	Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state	J Clin Invest. 2010;120(7):2355–2369
Duca FA et al	Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats	Nat Med. 2015;21(5):506–511
Graham GG et al	Clinical pharmacokinetics of metformin	Clin Pharmacokinet. 2011;50(2):81–98
UK Prospective Diabetes Study Group (UKPDS 34)	Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes	Lancet. 1998;352(9131):854–865
Salpeter SR et al	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus	Cochrane Database Syst Rev. 2010;(4):CD002967
de Jager J et al	Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency	BMJ. 2010;340:c2181
American Diabetes Association	Standards of Care in Diabetes—2024	Diabetes Care. 2024;47(Suppl 1):S1–S321
Inzucchi SE et al	Metformin in patients with type 2 diabetes and kidney disease: a systematic review	JAMA. 2014;312(24):2668–2675
Holman RR et al	10-year follow-up of intensive glucose control in type 2 diabetes	N Engl J Med. 2008;359(15):1577–1589